{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'End of Study', 'For studies without collection of human biologicals', 'samples or imaging data EoS is the Last Subject Last', '(Synonym of End of', 'Visit (LSLV).', 'Trial)', 'For studies with collection of Human Biologicals', 'Samples or imaging data, EoS is defined as the date of the', 'last testing/reading released of the Human Biological', 'Samples or imaging data, related to primary and', 'secondary endpoints. EoS must be achieved no later than', '8 months after LSLV.', 'Epoch:', 'An epoch is a set of consecutive timepoints or a single', 'timepoint from a single protocol. Epochs are defined to', 'support a main purpose which either to draw conclusions', 'on subject participation or to draw a complete conclusion', 'to define or precise the targeted label of the product.', 'Supporting means that data collected at the timepoints', 'included in an epoch must be sufficient to fulfil the', 'purpose of the epoch.', 'Typical examples of epochs are screening', 'immunogenicity follow-up, safety follow-up, ESFU,', 'follow-up.', 'eTrack:', \"GSK Biologicals' tracking tool for clinical/\", 'epidemiological trials.', 'Evaluable:', 'Meeting all eligibility criteria, complying with the', 'procedures defined in the protocol (see Section 9.3 for', 'details on criteria for evaluability).', 'Former smoker', 'A person who stopped smoking for at least 6 months.', 'GOLD grade:', 'The spirometric classification of airflow limitation in', '(classification of severity', 'COPD patients is based on post-bronchodilator FEV1 and', 'of airflow limitation in', 'can be divided into four GOLD grades [GOLD, 2013]:', 'COPD patients)', 'GOLD grade', 'In patients with FEV1 FVC < 0.70:', 'GOLD 1: Mild', 'FEV1 80% predicted', 'GOLD 2: Moderate', '50% FEV1 < 80% predicted', 'GOLD 3: Severe', '30% FEV1 < 50% predicted', 'GOLD 4: Very Severe', 'FEV1 < 30% predicted', '19-OCT-2018', '23', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Interventional Human', 'Studies in which participants are administered medical', 'Subject Research:', 'care, medicinal products and/or medical/scientific', 'procedures as described in a research protocol.', 'Non-interventional', 'Studies where medicinal products, should they be', '(observational) Human', 'administered, are prescribed in normal (routine) medical', 'Subject Research:', 'practice. No medical care or medical/scientific procedures', 'as required in a research protocol are administered to', 'participants except as part of routine medical care.', 'Pack-years of smoking:', 'Pack-years is a quantification of cigarette smoking, a way', 'to measure the total amount a person has smoked in the', 'course of his/her lifetime. The number of pack-years is', 'calculated as follows:', '(average number of cigarettes smoked per day X', 'number of years smoked)/20', 'E.g. a smoking history of 10 pack-years means having', 'smoked 20 cigarettes per day for 10 years, or having', 'smoked 10 cigarettes per day for 20 years.', 'Note: For the purpose of this study, pipe and/or cigar use', 'should not be used to calculate pack year history.', 'Research protocol:', 'A document that describes the objective(s), design,', 'methodology, statistical considerations, and organisation', 'of a study. The protocol usually also gives the', 'background and rationale for the study, but these could be', 'provided in other protocol referenced documents.', 'Prospective study:', 'A study in which the subjects/cases are identified and', 'then followed forward in time in order to address one or', 'more study objectives.', 'Protocol amendment:', 'The International Conference on Harmonisation (ICH)', 'defines a protocol amendment as: \"A written description', 'of a change(s) to or formal clarification of a protocol.', 'GSK Biologicals further details this to include a change', 'to an approved protocol that affects the safety of subjects,', 'scope of the investigation, study design, or scientific', 'integrity of the study.', 'Primary completion', 'The date that the final subject was examined or received', 'date:', 'an intervention for the purpose of final collection of data', 'for all primary outcomes, whether the clinical trial/', 'pharmaco-epidemiological study was concluded', 'according to the pre-specified protocol or was terminated.', '19-OCT-2018', '24', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}